Resources
218 Results (showing 51 - 60)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 10/23/2020 (updated 4/3/2024)
This article offers data regarding offering buprenorphine treatment at a public hospital primary care setting using a home, unobserved induction protocol.
Posted 10/23/2020 (updated 4/3/2024)
The goal of this module is to train providers to initiate patients on buprenorphine safely and effectively.
Posted 10/21/2020 (updated 4/3/2024)
This study sought to identify best practices for retaining individuals in treatment and for achieving continuity of care between settings.
Posted 9/1/2021 (updated 4/2/2024)
Posted 9/1/2021 (updated 4/2/2024)
Posted 8/25/2021 (updated 4/2/2024)
HRSA’s Health Centers Program published new research briefs exploring health center capacity in maternity care deserts, differences in clinical quality measures among Appalachian and non-Appalachian health centers, and the role of health centers in providing medication-assisted treatment. The briefs were developed through the UDS Mapper—a tool that helps evaluate the geographic reach, penetration, and growth of the Health Center Program and its relationship to other federally-linked health resources.
Posted 8/19/2021 (updated 4/2/2024)
In spring 2021, pharmaceutical manufacturers and distributors notified syringe services programs (SSPs) and partners that there would be significant interruptions in the supply of injectable/intramuscular (IM) naloxone. Currently, production and distribution delays are expected to last until fall 2021. This will specifically affect SSPs because IM naloxone is the most affordable formulation, and therefore is most commonly utilized by programs that distribute large volumes of naloxone to reduce fatal overdose rates.
Posted 8/19/2021 (updated 4/2/2024)
The PMHC Toolkit provides resources for law enforcement agencies to partner with service providers, advocates, and individuals with mental illness and/or intellectual and developmental disabilities (I/DD). The goal of these partnerships is to ensure the safety of all, to respond effectively, and to improve access to services and supports for people with mental illness and I/DD.
Posted 8/19/2021 (updated 4/2/2024)
Addiction Policy Forum, in partnership with Justice Community Opioid Innovation Network (JCOIN) and the National Judicial Task Force to Examine State Courts’ Response to Mental Illness, have released a new online course to help educate judges and court staff on the FDA-approved medications to treat opioid use disorder and their effectiveness for people involved with the criminal justice system.
The course is self-paced and takes approximately 30 minutes to complete. The course aims to prepare participants with the knowledge and information about what substance use disorder treatment involves, the differences between the types of medications used to treat opioid use disorder, and how those medications work.
Posted 8/4/2021 (updated 4/2/2024)